Avity Investment Management Inc. Has $159,000 Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Avity Investment Management Inc. increased its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 7.6% during the fourth quarter, HoldingsChannel reports. The fund owned 29,680 shares of the company’s stock after buying an additional 2,100 shares during the period. Avity Investment Management Inc.’s holdings in Corvus Pharmaceuticals were worth $159,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Samlyn Capital LLC increased its holdings in Corvus Pharmaceuticals by 160.7% during the 2nd quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after purchasing an additional 3,774,658 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Corvus Pharmaceuticals during the second quarter worth about $10,855,000. Geode Capital Management LLC grew its holdings in shares of Corvus Pharmaceuticals by 22.4% during the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock worth $2,974,000 after buying an additional 102,869 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in Corvus Pharmaceuticals by 64.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock valued at $724,000 after buying an additional 53,809 shares during the last quarter. Finally, State Street Corp lifted its stake in Corvus Pharmaceuticals by 48.2% in the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock valued at $941,000 after acquiring an additional 57,943 shares in the last quarter. 46.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CRVS. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Corvus Pharmaceuticals in a research note on Tuesday. Oppenheimer raised their target price on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, StockNews.com downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Corvus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $12.38.

Corvus Pharmaceuticals Trading Down 1.9 %

NASDAQ:CRVS opened at $5.10 on Wednesday. The stock has a market capitalization of $327.73 million, a PE ratio of -5.48 and a beta of 1.05. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.30 and a 1-year high of $10.00. The firm has a fifty day simple moving average of $7.20 and a 200 day simple moving average of $5.52.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.